Summary
PROJECT SUMMARY/ABSTRACT Cardiac allograft vasculopathy (CAV), a form of chronic rejection, is a leading cause of late graft failure and mortality after heart transplantation (HT). It is characterized by diffuse intimal thickening of the entire coronary tree, including the epicardial coronary arteries and microvasculature. Currently, therapies are initiated after identification of epicardial CAV on coronary angiography. However, they have limited efficacy once epicardial disease is detected. There remain substantial unmet needs in CAV prevention and treatment, due in part to a lack of fundamen
